US › Healthcare

Fate Therapeutics Inc (FATE)

US · Healthcare · Biotechnology

$2.57+2.80%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.3M
Revenue YoY
-20.3%
Net profit
$-31.2M
Profit YoY
+17.0%
EPS
$-0.26
EPS estimate
$-0.28
Net margin
-2,402.8%

EPS came in at -0.26 against a street estimate of -0.28 — a beat of 7.1%.

Key statistics

Market cap
$285.6M
Forward P/E
0.0
P/B
1.59
Book value
$1.55
EPS (TTM)
$-1.09
52-week high
$3.23
52-week low
$0.91
50-day MA
$2.44
200-day MA
$1.57
Beta
2.52

Analyst view

Analysts rate Fate Therapeutics Inc a buy (6 buy, 6 hold, 0 sell out of 12) with an average price target of $5.41.

Shareholding

Insiders
1.17%
Institutions
73.52%

Largest institutional holders

FundStake
Redmile Group, LLC11.04%
BlackRock Inc8.64%
Vanguard Capital Management, LLC3.60%
Vanguard Portfolio Management, LLC3.55%
Acadian Asset Management LLC3.53%
Two Sigma Investments LLC2.97%
Johnson & Johnson2.90%
AQR Capital Management LLC2.58%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Fate Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.